The comparison data produced by this study are expected to be used to develop strategies for future revisions of pharmacopoeias around the world. Moreover, on the basis of our findings, we suggest standards that require further collaboration among the pharmacopoeias in certain preferred areas. We identified the features of the monographs and general chapters listed in each pharmacopoeia, as well as differences across the pharmacopoeias. In this study, we analyzed monographs and general chapters listed in the three pharmacopoeias. We aimed to examine current differences among the Japanese Pharmacopoeia, the European Pharmacopoeia, and the United States Pharmacopeia–National Formulary and to identify areas that require further collaboration among the three pharmacopoeias. To contribute further to the protection of public health in the globalized drug market, we conducted a comparative study of the pharmacopoeias in Japan, Europe, and the United States. In addition, the International Meeting of World Pharmacopoeias has been held by the WHO to discuss information exchange and international collaboration, among other topics. For example, the Pharmacopoeial Discussion Group has worked to harmonize excipient monographs and general chapters. In recent years, pharmacopoeias around the world have harmonized their standards in the present context of globalized drug supply chains and markets. A pharmacopoeia’s core mission is to protect public health by creating and making available public standards to help ensure the quality of drugs.
0 kommentar(er)
